Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Antiarrhythmic

Therapeutic area intelligence for Antiarrhythmic with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 1

Companies

OMSAV Pharma →

Assets

Recent signals(5)

StrategyAugust 5, 2026

FDA Grants Approval for Dofetilide ANDA212496 by Innogenix Inc.

The FDA has granted approval for the ANDA212496 application for Dofetilide submitted by Innogenix Inc.

RegulatoryJuly 28, 2026

FDA Grants Approval for Flecainide Acetate by OMSAV Pharma

The FDA has granted approval for Flecainide Acetate under application ANDA218093 submitted by OMSAV Pharma.

RegulatoryJuly 9, 2026

FDA Grants AP Status for Sotalol Hydrochloride ANDA207428

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Sotalol Hydrochloride submitted by Regcon Holdings.

RegulatoryJuly 5, 2026

FDA Grants Approval for Flecainide Acetate ANDA218093 by OMSAV PHARMA

The FDA has granted approval for the ANDA218093 application for Flecainide Acetate submitted by OMSAV PHARMA.

RegulatoryJune 30, 2026

FDA Grants AP Status for Sotalol Hydrochloride ANDA207429

The FDA has granted approval status (AP) for the ANDA207429 application for Sotalol Hydrochloride submitted by Regcon Holdings.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.